Fang-Ping Xu
Overview
Explore the profile of Fang-Ping Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Y, Gao H, Li H, Hu Q, Du B, Li S, et al.
Int J Cancer
. 2024 Apr;
155(4):697-709.
PMID: 38577882
Patient-derived organoids (PDOs) may facilitate treatment selection. This retrospective cohort study evaluated the feasibility and clinical benefit of using PDOs to guide personalized treatment in metastatic breast cancer (MBC). Patients...
2.
Xu J, Xu F, Liu Z, Cui Q, Zhang K, Li Z
Medicine (Baltimore)
. 2022 Jul;
101(29):e29668.
PMID: 35866817
Background: To investigate the correlations between mutations in the telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase (IDH) 1 and 2 mutations or 1p/19q deletion in human gliomas. Methods: TERT...
3.
Feng H, Chen Y, Xie Z, Jiang J, Zhong Y, Guo W, et al.
Thorac Cancer
. 2021 Sep;
12(19):2564-2573.
PMID: 34490728
Background: Src homology region 2 domain-containing phosphatase 2 (SHP2) is a novel target for Kirsten rat sarcoma oncogene (KRAS) mutant cancer. We retrospectively studied the significance of SHP2 in KRAS...
4.
Tang W, Wu M, Bao H, Xu Y, Lin J, Liang Y, et al.
J Thorac Oncol
. 2021 Mar;
16(7):1136-1148.
PMID: 33722707
Introduction: Metastasis is the primary cause of lung cancer-related death. Nevertheless, the underlying molecular mechanisms and evolutionary patterns of lung cancer metastases are still elusive. Methods: We performed whole-exome sequencing...
5.
Zhang C, Zhang J, Xu F, Wang Y, Xie Z, Su J, et al.
J Thorac Oncol
. 2019 Aug;
14(11):1912-1923.
PMID: 31446140
Background: Understanding the genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma may provide critical insight and facilitate development of novel strategies for early detection and...
6.
Liu Z, Wang K, Lin D, Xu J, Chen J, Long X, et al.
Breast Cancer Res Treat
. 2019 Feb;
175(1):51-57.
PMID: 30712197
Objectives: Human epidermal growth factor receptor 2 (HER2, ERBB2) is a valuable prognostic and predictive biomarker in breast cancer. Accurate assessment of HER2 status is essential in selecting the patients...
7.
Xu F, Wang K, Xu J, Chen J, Zhang Y, Wu H, et al.
Breast Cancer Res Treat
. 2017 Sep;
166(3):757-764.
PMID: 28861637
Purpose: The updated 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing have made some major changes in HER2...
8.
Xu F, Liu Y, Luo X, Zhang F, Zhou H, Ge Y, et al.
Cancer Med
. 2016 Oct;
5(12):3500-3511.
PMID: 27781415
Steroid receptor coactivator-3 (SRC-3), a transcriptional coactivator for nuclear receptors and other transcription factors, plays an important role in the genesis and progression of several cancers. However, studies investigated the...
9.
Yan L, Liu Y, Xiang J, Wu Q, Xu L, Luo X, et al.
Int J Oncol
. 2015 Dec;
48(2):471-84.
PMID: 26676464
We have previously shown that dysregulation of miR-21 functioned as an oncomiR in breast cancer. The aim of the present study was to elucidate the mechanisms by which miR-21 regulate...
10.
Zhong W, Su J, Xu F, Zhai H, Zhang X, Yang X, et al.
Lung Cancer
. 2015 Sep;
90(2):205-11.
PMID: 26391021
Objectives: Most lung adenocarcinomas consist of mixtures of histological subtypes harboring different frequencies of driver gene mutations. However, little is known about intratumoral heterogeneity(ITH) within histologically heterogeneous primary lung cancers....